Sulfur-containing heterocycles derivatives as antioxidants  and nonenzymatic glycosylation of proteins blockersfor correction of experimental diabetes mellitus: extended abstract of dissertation for scientific degree of candidate of biological sciences: speciality 03.01.04 - biochemistry by Savateeva E. A. (Ekaterina Andreevna)
Manuscript copyright 
 
 
 
 
 
 
 
 
 
SAVATEEVA  
EKATERINA ANDREEVNA 
 
 
 
SULFUR-CONTAINING HETEROCYCLES DERIVATIVES AS ANTIOXIDANTS 
  AND NONENZYMATIC GLYCOSYLATION OF PROTEINS BLOCKERS 
FOR CORRECTION OF EXPERIMENTAL DIABETES MELLITUS 
 
 
 
03.01.04 - biochemistry 
 
 
 
 
 
  
EXTENDED ABSTRACT OF DISSERTATION  
for scientific degree of candidate of Biological Sciences 
 
 
 
 
 
Kazan, 2015 
The work is made in Institute of Chemical Engineering of Federal State Autonomous Educational 
Institution of Higher Professional Education «Ural Federal University named after first President of 
Russia B.N. Yeltsin» 
 
 
Scientific advisor:    member of the Russian Academy of Sciences,  
Doctor of Medical Sciences, professor   
     Chereshnev Valery Aleksandrovich 
Ph. D. in Medicine  
     Emelyanov Victor Vladimirovich 
     
Official opponents:   
 
Tseilikman Vadim Eduardovich – Doctor of Biological Sciences, professor, head of department of 
biochemistry in the State Budget Educational Institution of Higher Professional Education «South Ural 
State Medical University», Chelyabinsk 
 
Shumaev Konstantin Borisovich – Doctor of Biological Sciences, senior research assistant  of 
biochemistry of nitrogen fixation and nitrogen metabolism laboratory, Institute of Biochemistry named 
after A.N. Bakh, Federal State Institution "Federal Research Center “Fundamental principles of 
Biotechnology” the Russian Academy of Sciences", Moscow 
 
External reviewer: 
Federal State Budget Institution "Endocrinology Research Center," of Ministry of Health of Russia, 
Moscow 
 
Ph.D. defense will take place «24» September 2015 at 13.00 o’clock at the meeting of the 
Dissertation Committee D 212.081.08 of the FSAEI of HPE “Kazan (Privolzhsky) Federal University” 
at the address: 420008, Kazan, Karl Marx St., 74, aud.206. Phone: 7(843)23-37-842. 
The dissertation is available at the library named after N. I. Lobachevsky of the FSAEI of HPE 
“Kazan (Privolzhsky) Federal University” at the address: 420008, Kazan, Kremlyovskaya St., 35. 
The electronic version of the extended abstract of the dissertation is available on the official 
website of the FSAEI of HPE “Kazan (Privolzhsky) Federal University” www.kpfu.ru. 
 
 
 
  Extended abstract of dissertation dispatched «___»                  2015 
 
 
 
Scientific Secretary of the Dissertation 
Committee, Doctor of Biological Sciences, 
professor  
Abramova Z.I. 
                                               
  
2 
 
GENERAL DESCRIPTION OF THE WORK 
 
Relevance of the work. Modern medicine is experiencing a need for new pharmaceuticals to 
treat diabetes mellitus (DM) – widespread and socially significant disease (Dedov I.I. Innovative 
technologies in the treatment and prevention of diabetes and its complications // Diabetes mellitus. 
2013. Vol. 3. pp. 4 – 10). When searching for new antidiabetic agents, experimental modeling of the 
disease in animals is widely used. In order to optimize this stage of the search for antidiabetic agents, it 
is necessary to clearly imagine on what mechanisms the development of experimental and clinical DM 
a new compound is capable to influence.  
Two pathological processes, realized in conditions of chronic hyperglycemia, could be attributed 
to the number of potential targets for antidiabetic agents - nonenzymatic glycosylation of proteins 
(NGP) and oxidative stress (Balabolkin M.I. Diabetology // М.: Medicine, 2000. 672 p.; Monnier 
V.M., Sell D.R. Prevention and repair of protein damage by the Maillard reaction in vivo // 
Rejuvenation Res. 2006. V. 9, № 2. P. 264 – 273; Aldini G., Vistoli G., Stefek M. et al. Molecular 
strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end 
products // Free Radical Research. 2013. V.47, (Suppl. 1). P. 93 – 137). 
NGP is a spontaneous chemical reaction between the amino groups of the protein molecule and 
the carbonyl groups of monosaccharides and the subsequent conversion of the resulting compound, 
occurring without enzymes. Occurring changes disturb ionic interactions in protein molecules, 
changing the conformation, solubility, and therefore - the functional properties and sensitivity to 
proteases. It has been shown that enzymatically glycosylated in vitro insulin partially loses the ability 
to lower blood glucose and to stimulate glucose transport into cells when administered to animals  
(Hunter S. J., Boyd A. C., O’Harte F. P.M. et al. Demonstration of glycated insulin in human diabetic 
plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in 
humans // Diabetes. 2003. V. 52. P. 492 – 498; McKillop A.M., Mooney M.H, Harriott P. et al. 
Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay 
// Biochem. Biophys. Res. Commun. 2011. V. 286. Р. 524 – 528).  
Complex of metabolic disorders typical for DM, leads to oxidative stress - imbalance between 
pro- and antioxidants, accumulation of products of free radical oxidation (FRO) of lipids, proteins, 
nucleic acids (Evans J.L., Maddux B.A., Goldfine I.D. et al. The molecular basis for oxidative stress-
induced insulin resistances // Antioxid. Redox Signal. 2005. V. 7, № 7-8. pp. 1040-1052; 
Menshchikova E.B., Zenkov N.K., Lankin V.Z. et al. Oxidative stress: the pathological conditions and 
diseases // Novosibirsk: ARTA, 2008. 284 p.; Shumaev K.B., Gubkin S.A., Kumskova I.M. et al. The 
mechanism of formation of superoxide radical by reacting L-lysine with dicarbonyl compounds // 
Biochemistry. 2009. Vol. 74, №4. pp. 568-574). There is significant evidence of the effectiveness of 
sulfur-containing antioxidant and blocker of NGP – lipoic acid (LA) – in the treatment of DM and its 
complications (Stakhovskaya L.V., Guseva O. α-lipoic acid: pharmacological properties and clinical 
application. Review of the literature // Moscow, Russian State Humanitarian University, 2003. 63 p .; 
Ziegler D., Tritschler H.-J., Strokov I.A. Ametov A.S. et al. Treatment of diabetic polyneuropathy with 
thioctic acid (review) // Farmateka. 2008. V. 17, №171. pp 28 - 35; Shay K.P., Moreau R.F., Smith 
E.J. et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential // 
Biochim. Biophys. Acta. 2009. V. 1790. P. 1149 – 1160). However, it is an open question whether is 
possible to improve the results of treatment of DM by use of synthetic sulfur-containing compounds 
that have properties of antioxidants and blockers of NGP. 
In this regard, attention is attracted to synthetic sulfur-containing compounds of class 1,3,4-
thiadiazine (1,3,4-TD) and 2,4-substituted thiazoles. Have been reported about antioxidative and 
radioprotective activity of the representatives of these classes of compounds (Pfeiffer W.-D.         
1,3,4-Oxadiazines and 1,3,4-Thiadiazines // Compr. Heterocycl. Chemistry III. 2008. V. 9. P. 401 – 
455; Rasina L.N., Perova N.M., Novikova A.P., Chupakhin O.N. Structure, behavior in the body and 
biological activity of triazole derivatives // Proceedings of the First International Conference 
"Chemistry and Biological Activity of nitrogen heterocycles and alkaloids"; ed. V.G. Kartsev and G.A. 
Tolstikov. M., 2001. V.2. P.246). 2-aminothiazole and thiazolidinedione derivatives possess 
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antidiabetic activity (De S., Adhikari S., Tilak-Jain J. et al. Antioxidant activity of an aminothiazole 
compound: possible mechanisms // Chem. Biol. Interact. 2008. V. 173. P. 215 – 223; Spasov A.A., 
Petrov V.I., Cheplyaeva N.I. Lenskaya K.V. et al. Fundamental bases of the drugs research for the 
treatment of type 2 diabetes // Bulletin of Medical Sciences. 2013. № 2. pp. 43 - 49). It was shown that 
in aqueous solutions the 1,3,4-TD derivatives can be transformed into thiol derivatives, which 
according to our hypothesis, can bind glucose and NGP carbonyl intermediates, and possess 
antioxidant properties. However, antidiabetic activity of the 1,3,4-TD derivatives and 2,4-substituted 
triazoles have not previously been studied. The abovesaid defined the goal and objectives of this work. 
  
The goal of the present work is evaluation of ability of the sulfur-containing heterocyclic 
derivatives to exhibit antioxidant activity, to block NGP and to correct the metabolic disorders in 
experimental DM. 
 
Objectives: 
1. To screen compound of classes 1,3,4-TD  derivatives and substituted 2,4-thiazoles for ability to 
block reaction of nonenzymatic glycosylation of bovine serum albumin (BSA) with glucose in 
vitro.  
2. To study the antioxidant activity of the 1,3,4-TD derivatives in a model of inhibition of 
ascorbic acid (AA) oxidation with atmospheric oxygen. 
3. To evaluate the ratio of lipo- and hydrophilic properties of the of 1,3,4-TD derivatives with 
antioxidant and antiglycosylative activity in octanol/water. 
4. To study the effect of the 1,3,4-TD derivatives and 2,4-substituted thiazoles on biochemical 
parameters of rats’ blood and internal organs in alloxan DM. 
5. To find out the relationship between the structure, lipophilic, antioxidant, antiglycosylation 
properties of the 1,3,4-TD derivatives and their ability to correct metabolic disorders in 
experimental DM.  
6. To carry out a kinetic analysis of the reaction of NGP and its inhibition with reduced 
glutathione (G-SH) on the example of genetically engineered human insulin.  
 
 
The present work was financially supported by Russian Foundation for Basic Research (RFBR 
grants № 12-04-31852_mol_а and RFBR –“Ural” № 10-04-96097) and “UrFU Development 
Programme for 2010 – 2020 years”.  
 
Scientific novelty. First shown that the 1,3,4-TD and 2,4-substituted thiazole derivatives are able 
to inhibit the accumulation of NGP products while incubating BSA with glucose. Established that the 
best antiglycosylation properties have 5-phenyl-1,3,4-TD derivatives with an oxygen-containing 
hetaryl or alkylamino substituent at 2-position. 
 The evaluation of lipophilicity of potential NGP inhibitors – 1,3,4-TD derivatives – was 
performed in octanol/water. Established that the partition coefficient lgКow for active NGP inhibitors 
was 2.90 - 3.19, while for the less active inhibitors was 3.14 - 4.02. 
For the first time the ability of 1,3,4-TD derivatives to inhibit the oxidation of ascorbic acid 
with  atmospheric oxygen is demonstrated. The most active compounds are N-32, TD-79, L-92, L-17, 
L-34.  
For the first time in the model of alloxan DM in rats detected antidiabetic activity of 1,3,4-TD 
derivatives (L-17, L-14, N-32, L-31, L-91) and 2-guanidine-4-pyridinethiazole (2-G-4-PT). Studied 
1,3,4-TD derivatives have the ability to correct hyperglycemia, accumulation of products of NGP in 
blood and internal organs, and also possess antioxidant activity. 2-G-4-PT decreases accumulation of 
products of NGP and of lipids FRO in the blood and the internal organs, without affecting blood 
glucose levels. 
Proposed and experimentally confirmed the kinetic model of the process of nonenzymatic 
glycosylation of genetically engineered human insulin in vitro. Determined rate constants of the 
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forward and reverse reactions in the elementary step 2, the ratio of the rate constants of the forward 
and reverse reactions in the elementary step 1, and thermodynamic equilibrium constants of both steps. 
It is found that in the range of physiological concentrations natural thiol G-SH has a dose-
dependent ability to inhibit glycosylation of insulin with glucose in vitro, kinetic analysis of the 
process was performed. 
 
Statements to be defended: 
1,3,4-TD and 2,4-substituted thiazole derivatives are able to block reaction of NGP. The best 
antiglycosylation properties have 5-phenyl-1,3,4-TD derivatives with an oxygen-containing hetaryl or 
alkylamino substituent at 2-position, and having octanol/water partition coefficient lgКow in a range of 
2.90 – 3.19. 
1,3,4-TD derivatives are able to inhibit the oxidation of ascorbic acid with atmospheric oxygen. 
The most active are derivatives of 1,3,4-TD having morpholino substituent at the 2-position and 
thiophene, phenyl, p-fluorophenyl at 5-position. 
The antioxidant and antiglycosylation properties of 1,3,4-TD and 2,4-substituted thiazole 
derivatives enable to partially correct metabolic disorders in the development of alloxan DM in rats.  
As a result of the kinetic study of the reaction of nonenzymatic glycosylation of genetically 
engineered human insulin (GEHI) and its inhibition with G-SH, proposed the mathematical model of 
the reaction, verified its compliance with the results of the in vitro experiment, calculated rate 
constants and equilibrium constants for the FA formation steps in the absence and presence of G-SH. 
 
Practical relevance. During the screening have been found compounds able to decrease the 
accumulation of fructosamine (FA) – primary product of NGP reaction, to inhibit AA oxidation with 
atmospheric oxygen. Revealed some aspects of "structure-activity" relation, providing to conduct a 
targeted search and synthesis of compounds with antiglycosylative and antioxidant activities. Use of 
compounds which combine properties of antioxidant and of NGP blocker, is a promising approach for 
the pharmacological correction of DM in experiment.  
 
Approbation of the work and publications. 16 scientific papers adapted from the dissertation 
were published, 3 of them in journals included in the list of HAC. 1 application for an invention was 
filed, № 2014151103 (priority on December 16, 2014). The results were reported (with the publication 
of abstracts) in international and Russian conferences: 
 Russian conference "Actual problems of theoretical and applied biochemistry" (Chelyabinsk, 
2009); Annual Conference "Pharmacy and Public Health" (Ekaterinburg, 2010); XX Russian Youth 
Scientific Conference "Problems of Theoretical and Experimental Chemistry" (Ekaterinburg, 2010); I 
International scientific and practical conference "High technology, fundamental and applied research 
in physiology and medicine" (St. Petersburg, 2010); Annual Conference "Pharmacy and Public Health" 
(Ekaterinburg, 2011); All-Russian scientific and practical conference of biochemists and experts in 
laboratory medicine "Medical Biochemistry and clinical laboratory diagnostics in terms of 
modernization of the scientific research" (Omsk, 2011); II International scientific and practical 
conference "High technology, fundamental and applied research in physiology and medicine" (St. 
Petersburg, 2011); IX All-Russian Conference "Chemistry and medicine" with the Youth Scientific 
School on Organic Chemistry (Ufa, 2013); I scientific and practical conference of students and 
postgraduates of Russia "Chemistry in federal universities" (Ekaterinburg, 2013); Russian scientific 
and practical conference with international participation "Actual problems of medical biochemistry 
and clinical laboratory diagnostics" (Kazan, 2013); Ural Scientific Forum "Contemporary Problems of 
Organic Chemistry" (Ekaterinburg 2014); II All-Russian conference "Fundamental glycobiology" 
(Saratov, 2014); Russian scientific forum in the Ural "Actual issues of fundamental medicine" 
(Ekaterinburg 2014).    
 
Personal contribution of the author. The author participated in the planning of the research, 
performed a literature search, was directly involved in experiments in vitro, carried out biochemical 
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studies of blood and organs of experimental animals, conducted the calculations and experimental 
verification of the glycosylation reaction kinetic model. The material presented in the abstract, was 
collected, processed and analyzed by the author personally. 
The structure and scope of the work. Dissertation is stated on 160 pages. Dissertation 
comprises sections: introduction, review of literature, materials and methods, study results, discussion 
of the results, conclusions, references. The work contains 25 tables and 39 figures. References section 
comprises 225 sources, including 141 source in foreign languages. 
 
CHAPTER1. REVIEW OF LITERATURE 
 
The review of literature considers the biochemical mechanisms of metabolic disorders 
development in DM, existing approaches to their pharmacological correction, chemistry and biological 
activity of natural and synthetic sulfur-containing heterocyclic compounds of classes 1,3,4-TD and 
substituted thiazoles. 
   
CHAPTER 2. MATERIALS AND METHODS 
 
The study used 1,3,4-TD derivatives and 2,4-substituted thiazole derivatives, synthesized at the 
Department of Organic Chemistry of Institute of Chemical Engineering of Federal State Autonomous 
Educational Institution of Higher Professional Education «Ural Federal University named after first 
President of Russia B.N. Yeltsin» (PhD in Chemistry Sidorova L.P., PhD in Chemistry Perova N.M., 
PhD in Chemistry Tseitler T.A., PhD in Chemistry Novikova A.P.) under the supervision of the 
member of the Russian Academy of Sciences О.N. Chupakhin. As reference compounds we used the 
reduced and oxidized glutathione, aminoguanidine (Sigma, USA) and metformin (“Glucophage”, 
Nycomed, Germany). The ability of the tested compounds to block the reaction of NGP was evaluated 
by the accumulation of the initial NGP product FA when incubating BSA with glucose in the presence 
of 1,3,4-TD derivatives and substituted 2,4-thiazoles. 
In simulated aqueous solution, comprising BSA at a concentration of 5 g/L and glucose at a 
concentration of 20 mmol/L, were added abovementioned substances at a concentration of 20 mmol/L 
as inhibitors of the reaction of NGP. System incubated at 4 °C, m-cresol at a concentration of 2.5 
mg/mL was added to a solution as a preservative.  
After 1, 2, 4, and 8 weeks, samples were taken to determine the concentration of the initial 
NGP product FA (see Viktorova L.N., Gorodetsky V.K. The colorimetric method for determining the 
nonenzymatic glycated albumin and hemoglobin // Lab. matter. 1990. Vol. 5. pp. 15 – 18).  
Antioxidant activity of 1,3,4-TD derivatives was evaluated by effect on AA oxidation rate with  
atmospheric oxygen. For that TD-1,3,4 and AA were dissolved in water in ratios 1:1 and 1:2, 
respectively, and incubated at 37 °C with vigorous stirring for 6 hours. Samples were taken every hour 
and a concentration of AA in the solutions was established titrimetrically with 2,6-
dichlorophenolindophenol (Davies M.B., Partridge D.A., Austin J.A. Vitamin C: Its Chemistry and 
Biochemistry // M.: Mir, 1999. 176 p.). Based on the findings, graphs of decrease in concentration of 
АA in the presence of each test substance were plotted. Concentrations decrease rates were calculated 
by the formula 𝑣𝑣 =  ∆𝐶𝐶/∆𝑡𝑡, wherein ∆𝐶𝐶 is  a change of АA concentration, ∆𝑡𝑡 is an incubation time. 
To evaluate hydro- and lipophilic properties ratios of 1,3,4-TD derivatives, determined 
“water/octanol” partition coefficient by slow stirring method (All-Union State Standard 32291-2013).  
“Water/octanol” partition coefficient (Kow) is a ratio of equilibrium concentrations of a 
compound dissolved in a biphasic system consisting of two substantially immiscible solvents. The 
results are given in the form of a common logarithm (lgKow) (Rutkowska E., Pajak K., Jóźwiak K. et 
al. Lipophilicity – methods of determination and its role in medicinal chemistry // Acta Pol. Pharm. 
2013. V. 70, №1. P. 3 – 18).  
The experiment for evaluation the effect of sulfur-containing heterocyclic compounds on 
biochemical parameters of blood and internal organs in experimental DM was performed at the 
Institute of Immunology and Physiology, Ural Branch of Russian Academy of Sciences (Doctor of 
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Biological Sciences Danilova I.G., Ph.D. in Biology Gette I.F., Junior Researcher Bulavintseva T.S., 
Director - member of the Russian Academy of Sciences, Doctor of Medical Sciences Chereshnev 
V.A.) 
Alloxan DM was modeled on 50 white mongrel male rats weighing about 200-250 g. The 
animals were kept in a laboratory vivarium, wherein the temperature was kept constant in the range of 
22 - 25 °C and the natural alternation of day and night. All animals had free access to food and water.  
Cleaning of the cells was carried out daily, disinfection – weekly. All manipulations with animals were 
carried out in compliance with ethical principles and in accordance with Directive 2010/63 / EU of the 
European Parliament and of the Council of 22 September 2010 on the protection of animals used for 
scientific purposes. 
Alloxan DM was modeled by tree-time intraperitoneal administration of alloxan in a total dose 
of 300 mg/kg animal body weight. Simultaneously with the induction of DM compounds L-17, L-14, 
H-32, L-31, L-91 and 2-guanidine-4-piridintiazol hydrobromide were administered in a dose of 40 
mg/kg animal body weight 3 times a week for 4 weeks. Substances were previously dissolved in 
injectable water. LA (“Octolipen”, Russia) in similar doses was used as a reference substance. 
Upon termination of the experiment concentrations of glucose (by the glucose oxidase method) 
and of total protein (by biuret method) were determined in the animals' blood (Kamyshnikov VS 
Handbook of clinical and biochemical laboratory diagnostics: in 2 V. // Minsk: Belarus, 2000 V.1, 495 
pp., V.2, 463 pp.). To characterize the activity of NGP concentration of FA in plasma and liver and 
kidney homogenates was determined in the animals (Viktorova L.N., Gorodetsky V.K. The 
colorimetric method for determining the enzymatic glycosylated albumin and hemoglobin //Lab. 
science. 1990.V 5. pp. 15 - 18) and HbAlc in the blood by column chromatography sets "Diabetes test" 
("Fosfosorb", Russia). Activity of FOR of lipids was assessed by concentration of MDA in the plasma 
(Stalnaya I.D., Garishvili T.G. Method for determination of malondialdehyde by using thiobarbituric 
acid // Modern methods in biochemistry; ed. V.N. Orekhovich. M., 1977, pp. 66 - 68) and catalase 
activity of whole blood (Bakh A.N., Zubkova S.A. On the question of catalase // Collection of selected 
works. Leningrad. 1937. рp. 241 - 245). 
Kinetic analysis of reaction of nonenzymatic glycosylation of GEHI and its inhibition by G-SH 
was performed in cooperation with an assistant professor of Physical and Colloid Chemistry 
Department of Chemical Technology Institute of Ural Federal University, Ph.D. in Chemistry N.K. 
Bulatov. 
 
 
CHAPTER 3. STUDY RESULTS AND DISCUSSION  
 
Section 3.1. Antiglycosylation and antioxidant activity of 1,3,4-TD derivatives  
 
Section 3.1.1. Study of 1,3,4-TD derivatives’ ability to block reaction of nonenzymatic 
glycosylation of BSA with glucose in vitro   
 
The possibility of using natural and synthetic thiols for correction NGP in vivo is limited by 
their low bioavailability and rapid inactivation by oxidation to disulfides. In this connection, research 
of activity of synthetic substances, which can be transformed into thiol derivatives in the cells, is 
evidently promising. This kind of transformation is typical for 1,3,4-TD derivatives, which may 
explain their wide spectrum of biological activity.  
 
S
N
N
R1
R2
N
N
R1
R2
SH
H
 
Among the 41 compounds screened, we selected the 12 most active substances, inhibiting 
accumulation of FA by 20 - 70% compared to control values (see Fig. 1). 
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Fig. 1. Accumulation of FA when incubated BSA with glucose in the presence of 1,3,4-TD derivatives, 
% to the level of the control experiment of the corresponding week of the experiment. 
Reference compound – G-SH. 
 
The effect of these compounds manifested throughout the experiment in contrast with G-SH, which 
had lost activity up to 8 weeks. Compounds exhibiting maximum antiglycosilation activity, differ from 
low active compounds by the nature of the substituents at 2- and 5-positions  of thiadiazine cycle (see 
Table 1).  
Table 1                                                                                                                          
1,3,4-TD derivatives, effectively inhibiting the accumulation of FA 
Compound 
Substituent 
Compound 
Substituent 
R1 R2 R1 R2 
L-17 
N
O
  
N-80 N
 O  
LT-17 
NH OH(CH2 )2
  
LT-10 N
H
 
F
 
N-10 
N
O
     
Br
 
N-32 N
 S  
LT-4  
     
Cl
 
TD-79 N
O
 
S
 
LT-1  
   
L-34 
 
 
L-20 N
O
     
OH
 
L-14 
 
 
N
H
N
H
N
O
CH3
CH3
NH N O(CH2)3
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Among active inhibitors a combination of phenyl at 5-position and of morpholine or other 
oxygen-containing alkylamino moiety at 5-position is typical. Among the compounds with the lowest 
antiglycosilation activity prevail compounds containing dichlorothiophene substituents at 5-position, 
irrespective of the nature of the substituent at 2-position. 
The mechanism of antyglycosylation action of the compounds of 1,3,4-TD class is possibly 
associated to their ability to be transformed into SH-substituted pyrazoles, as has been observed by 
heating certain 1,3,4-TD in acidic and alkaline media, or to attach glucose to the moiety of the 
thiadiazine ring after its opening (see Fig. 3). It can be assumed that the presence of oxygen at            
2-position of alkylamine moiety reduces electron-donor properties of nitrogen involved in the p-π 
conjugation with thiadiazine cycle, thereby contributing to the ring opening with carbon-sulfur bond 
cleavage. 
 
 
Section 3.1.2. Study of antioxidant properties of 1,3,4-TD derivatives in a model of AA oxidation 
with  atmospheric oxygen 
 
AA exhibits antioxidant properties synergistically with other natural antioxidants. It is known 
that ascorbate reduces vitamin E phenoxide radical, being oxidized to dehydroascorbate, and thiol 
compounds reduce dehydroascorbate to AA. Ascorbate content in the blood of patients with DM is 
decreased and correlates negatively with the level of HbAlc (Kositsawat J., Freeman V.L. Vitamin C 
and A1c relationship in the National Health and Nutrition Examination Survey (NHANES) 2003-2006 
// J. Am. Coll. Nutr. 2011. V. 30, № 6. P. 477 – 483).  
 
 
 
Fig. 2. Evaluation of the L-17 compound effect on the kinetics of the AA oxidation by atmospheric 
oxygen. 
 
To evaluate antioxidant properties of 1,3,4-TD derivatives, their ability to inhibit AA oxidation 
with  atmospheric oxygen was evaluated. 
In the context of compound L-17 (see Fig.2) it can be seen that concentration of AA in the 
tested solutions decreases over time, but AA oxidation with atmospheric oxygen in the control occurs 
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faster than in the presence of the compound L-17. AA rate of decay in the absence of the inhibitor 
was15.0 µg/L·h, in the presence of equimolar amounts of the L-17 it decreased to 11.5 µg/L·h, and in 
2-fold excess of the L-17 – to 8.5 µg/L·h. The conducted experiments have shown that the compound 
L-17 has a dose-dependent ability to prevent the oxidation of the AA.  
The experiment was conducted also with seven representatives of the class 1,3,4-TD, LA and 
glutathione in oxidized and reduced forms. From the data obtained rates of decline in concentrations of 
AA in tested solutions were calculated (see Table. 2). 
 
Table 2 
Oxidation rate of AA with atmospheric oxygen in the presence of the sulfur-containing compounds 
 
Compounds 1:1 1:2 
v, mg/L·h % C v, mg/L·h % C 
GSH 9,78±0,49 50±2,5 2,44±0,12 57±2,8 
GSSG 16,56±0,83 72±3,6 14,67±0,73 72±3,6 
LA 29,33±1,47 86±4,3 29,33±1,46 86±4,3 
TD-79 6,98±0,35 17±0,8 10,48±0,52 30±1,5 
L-92 18,33±0,92 78±3,9 10,86±0,54 44±2,2 
N-32 16,10±0,81 62±3,1 7,33±0,37 28±1,4 
L-31 25,88±1,29 75±3,7 32,59±1,63 100±5 
L-34 39,01±1,95 100±5 23,33±1,16 56±2,8 
L-17 28,62±1,43 72±3,6 21,46±1,07 53±2,6 
LT-1 33,17±1,66 130±6,5 36,67±1,83 123±6,1 
L-14 73,33±3,67 650±32,5 71,90±3,59 625±31,2 
*% C – percentage to  the level of the control experiment 
 
According to the data given in the table, it can be concluded that the highest antioxidant 
activity has compound TD-79, whereas compounds N-32, L-92, L-17 and G-SH prevent oxidation of 
AA slightly weaker. 
Compounds L-34 and L-31, and oxidized glutathione at two concentrations tested had an 
ambiguous effect on the kinetics of the AA oxidation and substances LT-1 and L-14 accelerated it 
altogether. 
The possible mechanism of this effect of 1,3,4-TDs we associate with the influence of its 
transformation products containing a thiol group. These compounds reduce dehydroascorbic acid to 
AA, while themselves being oxidized to disulfides (see Fig. 3). 
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Рис. 3. Binding of carbonyl compounds and reduction of dehydroascorbic acid in presence of  
1,3,4-TD derivatives.  
 
Analysis of the "structure-activity" relationship in the series of 1,3,4-TD derivatives changimg 
the kinetics of AA oxidation with atmospheric oxygen shows the dependence of the activity on the 
presence and nature of the substituents at the 2- and 5-positions of the thiadiazine cycle. Thus, among 
the 1,3,4-TD derivatives comprising a phenylic moiety at 5-position, the greatest antioxidant activity 
possessed by compounds L-17 and L-34 comprising morpholine, and at 2-position comprising 
dimethylmorpholine, respectively. On the other hand, among the morpholino substituted derivatives of 
1,3,4-TD, thiophene derivatives at the 5-position possess the highest antioxidant properties. The 
highest antioxidant activity among the studied synthetic compounds had 2-morpholino-5-thienyl-1,3,4-
TD (TD-79). 
 
Section 3.1.3. Study of the ratios between lipophilic and hydrophilic properties of 1,3,4-TD 
derivatives with antioxidant and antiglicosilation activity in octanol/water  
 
Interaction between biologically active substances and cellular and subcellular structures occurs 
in an aqueous medium or nonaqueous layers of membranes formed by hydrophobic lipid fragments. It 
was shown that increasing of lipophilicity corresponds with decreasing in water solubility, increasing 
the rate of penetration through the skin, increasing the degree of binding to plasma proteins, the 
material cumulation, which largely determines the biological activity of the compounds (Lu Y., Kim 
S., Park K. et al. In vitro-in vivo correlation: perspectives on model development // Int. J. Pharm. 2011. 
V. 418, №1. P. 142 – 148; All-Union State Standard 32291-2013). 
Coefficients lgКow of 10 1,3,4-TD derivatives, distinguished by antiglycosylation activity, were 
identified by slow stirring method (see Table 3). 
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Table 3 
Values of lgКow for 1,3,4-TD derivatives  in octanol/water  
 
Com-
pound LT-17 LT-4 L-17 TD-79 N-94 L-34 N-32 L-103 L-92 L-14 
lgКow 2,90 3,01 3,03 3,06 3,14 3,17 3,19 3,38 3,41 4,02 
 
When analyzing lgКow values of studied 1,3,4-TDs, were found expected differences in 
lipophilicity of compounds differing in the nature of the substituents at the 2- and 5-positions. For 
example, the compound 2-G-5-P has less bulky substituent at the 2-position of all compounds studied 
and has lower lipophilicity. Compound L-17 differing from the 2-G-5-P by less polar substituent at the 
2-position, has a higher coefficient lgКow. Compound L-34 has two additional methyl radical in the 
structure of morpholine moiety and thus has a greater lipophilicity in comparison with the L-17. 
Finally, the compound L-14 having the most aliphatic and the least polar substituent at the 2-position, 
naturally has been found to have the highest value lgКow.  
Arranging of 1,3,4-TD derivatives with different antioxidant activity by the ratio of lipophilic 
and hydrophilic properties failed to demonstrate the relationship between lgКow and the ability to 
inhibit the oxidation of AA with atmospheric oxygen. lgКow values of 1,3,4-TD derivatives with the 
highest antioxidant activity did not differ from those of the weak antioxidants.  
When comparing the lipophilicity and antiglycosylation activity of 1,3,4-TDs, the following 
facts had been identified. The partition coefficient lgКow for more active NGP inhibitors was 2.90 - 
3.19, while for the less active inhibitors was 3.14 - 4.02. Thus it can be concluded that optimal for 
manifestation of antiglycosylation activity of derivatives 1,3,4-TD is the value lgКow = 2.90 - 3.19. 
 
 
Section 3.2. Study of 2,4-substituted  thiazoles’ ability to block reaction  
of nonenzymatic glycosylation of BSA with glucose in vitro   
 
Synthetic derivatives of thiazole (thiamine) and guanidine (metformine) are used in the 
treatment of DM and its complications (Balabolkin M.I., Klebanova E.M., V.M. Kreminskaya 
Treatment of diabetes and its complications. Guidelines for doctors // M.: Medicine, 2005. 512 p.; 
Ametov A.S. Type 2 diabetes mellitus. Problems and Solutions // M.: GEOTAR Media, 2011. 704 p.). 
Aminoguanidine is a reference compound in the experimental evaluation of the ability of compounds 
to inhibit the NGP. However, guanidine-substituted thiazole derivatives previously were not subjected 
to studies on antidiabetic activities, and this has caused the formulation of the problem in this Section 
of the work.  
Compounds selected for study were triazole derivatives having guanidine, amino or morpholine 
at 2-position, and aryl or heteryl at 4-position (see Table 4). 
 
 
N
S
R2
R1  
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Table 4 
Structure of tested 2,4-substituted thiazole derivatives 
 
Compound 
Substituent 
Compound 
Substituent 
R1 R2 R1 R2 
2-guanidine-4-
phenylthiazole 
(2-G-4-PT) 
N
H
NH
NH2   
L-90 NH
N O(CH2 )3
    
2-guanidine-4-п-
aminophenylthiazol
e (2-G-4-APT) 
N
H
NH
NH2  NH2  
N-63 N O
  
2-guanidine-4-α- 
pyridinethiazole  
(2-G-4-α-PT)  
N
H
NH
NH2  N  
N-107 NH2  
Cl
 
2-guanidine-4-γ- 
pyridinethiazole  
(2-G-4-γ-PT) 
N
H
NH
NH2        N  
N-108 NH2  
EtO
 
2-guanidine-4-(5-
uracil) thiazole 
(2-G-4-UT) 
N
H
NH
NH2  
N
H
O
NH
O  
N-109 NH2  
OMe
MeO
 
 
 
Structure of these compounds, particularly presence of guanidine group, makes them probable 
inhibitors of NGP reaction by competition with the protein in the reaction with glucose and carbonyl 
intermediates. Moreover, aminoguanidine (AMG) and metformin (MF), whose activity as blockers of 
the NGP reaction has been proved earlier, were used in the experiment (Ozyazgan S., Unlucerci Y., 
Bekpinar S., Akkan A.G. Impaired relaxation in aorta from streptozotocin-diabetic rats: effect of 
aminoguanidine (AMNG) treatment // Int. J. Exp. Diabetes Res. 2000. V. 1, №2. P. 145 – 153; Chang 
K.C., Hsu K.L., Chou T.F. et al. Aminoguanidine prevents age-related deterioration in left ventricular-
arterial coupling in Fisher 344 rats // Br. J. Pharmacol. 2004. V. 142, № 7. P. 1099 – 1104; Lankin 
V.Z., Konovalova G.G., Tikhaze A.K., Nedosugova L.V. Influence of natural dicarbonyls on the 
activity of antioxidant enzymes in vitro and in vivo // Biomed. Сhemical. 2012. V. 58, no. 6. pp. 727 – 
736). Ability of substituted 2,4-triazoles to inhibit the NGP reaction was investigated similarly to the 
experiment with 1,3,4-TDs. 
From the data obtained (see Fig. 4) it can be concluded that the accumulation of FA in the 
model system “BSA with glucose” in the presence of guanidine derivatives of thiazole reduced as 
compared with the control, most of all - in the presence of 2-guanidine-4-phenylthiazole. In the case of 
p-aminophenyl derivative, FA concentration exceeded the control in 3.5 - 4 times during all periods of 
the experiment. We attribute this to the ability of the compound to form additional quantities of FA at 
the aminogroup of aminophenyl moiety. 
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Fig. 4. Accumulation of FA when incubated BSA with glucose in the presence of 2,4-substituted 
thiazole derivatives, % to the level of the control experiment of the corresponding week of the experiment. 
Reference compounds – aminoguanidine (AMG) and metformine (MF). 
 
A significant ability to inhibit the accumulation of FA in the later periods of the experiment 
showed thiazole derivatives containing at 2-position amino or morpholino group and phenyl or 
substituted phenyl at 4-position. The highest activity among them possesses 2-morpholino-4-phenyl-
thiazol (compound N-63). Thus, 4-aryl thiazoles having at 2-position guanidine group or morpholine 
are prospective for the search for NGP inhibitors group of synthetic sulfur-containing heterocyclic 
compounds. 
 
Section 3.3. Biochemical factors of blood and organs of rats in the development of alloxan DM on 
the background of the sulfur-containing heterocyclic compounds administration  
 
In the development of new drugs for the treatment of DM is widely used simulation of this 
disease in animal experiments. The leading role in the formation of diabetic vascular lesions and 
nerves plays activation of NGP and FRO of lipids, proteins, and nucleic acids caused by prolonged 
hyperglycemia. It is known that the natural thiol glutathione corrects condition of endocrine function 
of β-cells of the pancreas in experimental DM. In the experiment and clinic received numerous reports 
of successful correction of free radical processes and NGP, enhance the action of insulin in DM by 
introduction of the LA. 
Considering previously identified ability of a number of heterocyclic compounds of 1,3,4-TD 
and 2-guanidinetiazole class to inhibit the reaction of NGP in the model system, it is of interest to 
assess the ability of these compounds to effect biochemical factors of peripheral blood in experimental 
DM. 
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Table 5 
Biochemical factors of blood and organs of rats in the development of alloxan diabetes  
on the background of the sulfur-containing heterocyclic compounds administration, M± m 
Factor 
Controle 
(n=10) 
Tested compound 
LA 
(n=7) 
L-31 
(n=5) 
L-91 
(n=5) 
L-17 
(n=7) 
N-32 
(n=5) 
L-14 
(n=5) 
2-G-4-PT 
(n=6) 
Blood 
Glucose, mmol/L 34.6±3.4 14.8±1.7* 10.3±0.9* 13.7±1.9* 23.7±2.2* 25.2±5.2* 29.3±3.0* 33.4±2.5 
HbA1c, % 9.1±0.8 5.1±0.9* 6.9±0.3* 5.3±0.3* 6.5±0.7* 5.7±1.7* 7.5±0.7* 9.2±0.7 
Fructosamine, µmol/g of protein 4.7±0.5 3.1±0.4* 3.8±0.5 3.6±0.2* 3.2±0.9 3.8±0.8 5.3±0.6 3.2±0.5* 
Catalase, ncatal/g Hb 156±11 1094±95* 1025±87* 1222±70* 143±8 79±9* 165±10 138±22 
MDA, nmol/L 441±19 370±50 365±45 303 ±43* 106 ± 27* 370±22 620±68 191±28* 
Organs 
Fructosamine, kidney, µmol/g of 
protein 
45.2±3.8 16.3±1.3* 37.7±1.5 16.3±0.3* 15.6±2.2 23.9±2.0* 20.7±2.1* 17.3±0.9* 
Fructosamine, liver, µmol/g of 
protein 
20.9±8.0 3.7±0.3* 5.1±0.9* 9.3±0.8* 8.6±1.6* 9.4±1.3* 9.5±2.5* 8.3±1.2* 
* - statistically significant difference from control experiment, р < 0.05
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According to data of the Table 5, administration of alloxan led to persistent and severe 
hyperglycemia, accumulation of glycosylated proteins in the blood and organs of animals.  
Hyperglycemia and NGP activation could serve as a trigger for oxidative stress, MDA 
accumulation and decrease in blood catalase activity. Administration of LA significantly 
mitigated, though not eliminated entirely, biochemical disorders in the developing alloxan DM. 
Hyperglycemia and its related concentrations of glycosylated blood proteins were 35-55% lower 
comparing to the control group when administered LA. Contents of FA in homogenates of 
kidneys and liver was 2.8 and 5.6 times, respectively, less comparing to the control group when 
administered LA. The antioxidant effect of LA in the present study manifested by increase of 
catalase activity, however, the content of MDA in the blood has not undergone statistically 
significant changes. 
Studied synthetic sulfur-containing heterocyclic compounds are also able to partially 
correct metabolic disorders in the development of alloxan DM. However, actions of the 1,3,4-TD 
derivatives and of 2-G-4-PT were principally different. The 1,3,4-TD derivatives L-17, L-91, N-
32, and L-14 caused a decrease of hyperglycemia and HbA1c concentration in the blood, as well 
as FA in the kidneys and liver of the animals, similar to LA. Compound L-31 differed from the 
others 1,3,4-TD by the fact that did not reduce the accumulation of FA in the kidneys. The key 
insight of corrective action of 1,3,4-TD derivatives was the antihyperglycemic effect. 
1,3,4-TD derivatives antihyperglycemic effect intensity in the in vivo experiment 
decreased in line L-31 > L-91 >  L-17 > H-32 > L-14. By analyzing the relationship between the 
activity of the 1,3,4-TD derivatives in the experiment in vivo and in vitro, it should be noted that 
compounds H-32, L-31 and L-17, which actively inhibited oxidation of AA with atmospheric 
oxygen, had shown corrective activity in vivo greater than compound L-14, which accelerated 
the oxidation of AA in in vitro study and increased MDA accumulation in the blood of the 
animals. 
Administration of 2-G-4-PT did not decrease severity of hyperglycemia and 
accumulation of HbA1c, but statistically significantly decreased levels of MDA and FA in 
kidneys and liver. Thus, without having the antihyperglycaemic effect, 2-G-4-PT showed 
properties of antioxidant and blocker of NGP. 
The ability of LA and of the 1,3,4-TD derivatives to mitigate metabolic disorders in the 
developing alloxan DM we associate primarily with the protection of β-cells of islets of 
Langerhans against alloxan-induced oxidative stress, leading to the death of pancreatic endocrine 
cells. 
As the biological mechanism of this influence may be considered the ability of LA and of 
the 1,3,4-TD derivatives to transform into thiol derivatives, increasing the power of the 
antioxidant defense of β-cells. 2-G-4-PT, not having the ability to replenish the pool of 
intracellular thiols, apparently devoid of direct effects on β-cells. 
The protective effect of the compound at the developing alloxan DM may be explained 
by considering data of the antioxidant activity of substituted thiazoles and the ability of 
guanidine derivatives of thiazoles to inhibit NGP by reaction with glucose and carbonyl 
intermediates of NGP. 
Thus, in the current study, for the first time demonstrated the ability of synthetic sulfur-
containing heterocyclic compounds from 1,3,4-TD and 2-G-4-PT to correct the metabolic 
disorders in the development of alloxan DM in rats. Metabolic actions of representatives of two 
classes of sulfur-containing heterocycles differed: for 1,3,4-TD derivatives was typical 
antihyperglycemic, antioxidant and antiglycosylative effects, 2-G-4-PT had only the last two 
mechanisms of action. Efficacy of 1,3,4-TD derivatives in treatment of experimental DM 
detected parallels to their antioxidant activity in vitro. 
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Section 3.4. Kinetic analysis of reaction of nonenzymatic glycosylation 
of genetically engineered human insulin 
NGP is a complex multi-stage process, which could be conditionally divided into three stages. 
The initial stage of  NGP consists of 2 consecutive steps (see Fig. 5).  
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Fig. 5. Initial stage of NGP reaction 
 
The first step is forming of the Shiff’s base, which rearranges itself into a more stable 
Amadori product at the second step. In case of protein reacting with glucose, Amadori product 
has the structure of 1-deoxy-1-(N-aminoacyl)fructose (so-called “fructosamine”, FA). There are 
different  viewpoints about reversibility of the second stage. In this study kinetic analysis had 
been made in accordance with hypothesis that the second step is reversible. 
The second stage is fructosamine transformation into intermediate glycosylation products – 
carbonyl compounds (glyoxal, methylglyoxal et alias) (see Fig. 6). Formed carbonyl compounds 
are more active in reaction with protein than initial monosaccharide. 
 
Fig. 6. Scheme of formation certain products of NGP.  
Arg and Lys - lysine and arginine residues in the protein.  
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The final stage of the reaction is formation of advanced glycosylation products through 
acting between carbonyl compounds and protein molecule (see Fig. 6). Advanced glycosylation 
products formation irreversibly change native structure of protein. Inner and adjacent cross-
linking between protein amino groups mostly contribute to this process.  
Knowledge of kinetic principles of nonenzymatic glycosylation of insulin allows to offer a 
mechanism of interaction between glucose and protein, that will serve as a basis for developing a 
scientific approach to search and synthesis of NGP inhibitors. 
Experimental study of the kinetics of nonenzymatic glycosylation of insulin was carried 
out in base test solutions comprising GEHI and glucose in various concentrations. The solutions 
were incubated for 8 weeks, samples were taken periodically to determine the concentration of 
fructosamine.  
Obtained data on IFс  concentration changes in tested solutions with the course of time t are 
presented in Fig. 7. 
 
Fig. 7. Kinetic curves ntс )(IF  (n = 1, 2, 3, 4) for 0,OH2с = 55400  mol/m
3, 0,Iс = 0.872 mol/m
3  
and various 0,Gс , mol/m
3: 1 – 6.25; 2 – 12.5; 3 – 25.0; 4 – 50. Temperature Т = 277 К. 
 
Then linearization of kinetic curves was held for the subsequent mathematical treatment (see Fig. 
8), and established a series of equations that characterize the considered reaction step.  
 
Fig. 8. Linear patterns of kinetic curves ntс )(IF  (n = 1, 2, 3, 4) (see Fig. 2)  
in coordinates t and ( )( )IF,IF,IFln ссс eqeq −  for such choice of  
eqс ,IF , mol/m
3: 1 – 0.253; 2 – 0.290; 3 – 0.434; 4 – 0.637 
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By treatment of the experimental curves )(IF tс  using the kinetic equations of the process of 
nonenzymatic glycosylation of GEHI in vitro were determined: the rate constants of direct and 
reverse elementary reactions in step 2 ( dir2k =0.044715  1/h;
rev
2k =0.002158  1/h), the ratio of the 
rate constants of the forward and reverse elementary reactions in step 1 ( rev1
dir
1 kk =134.2), and 
the thermodynamic equilibrium constant of both steps ( сК1 =134.2;  сК2 =21.0). The equilibrium 
concentrations of all insulin-containing components – participants of the process. 
The process at the initial stage of its development is clearly manifested as a combination of 
two stages, having a bilateral character, the first of which is the interaction of insulin (I) and 
glucose (G), and leads to the formation of the intermediate - Schiff base (IG), and the second - in 
the formation of fructosamine (IF): 
1. I + G = IG + H2O,              
2. IG = IF,  
wherein the process occurs in quasi-equilibrium regime for the first stage. 
Then the model system was complicated by the addition of a third component of the 
reaction – G-SH – to reveal its ability to inhibit the reaction of NGP. The mathematical treatment 
of experimental results was carried out similar to the previous experiment. 
As a result it was found that G-SH additives do not alter the two-stage mechanism of the 
process occurring in quasi-equilibrium regime for the first stage, but significantly reduce its pace 
and a promotion degree due to the binding of insulin by the glutathione in a chemical compound 
IαY type according to path reaction р=3: 
 
3. αI + Y = IαY, 
wherein α is a module of stoichiometric coefficients of insulin.  
It was shown that in the presence of G-SH course of the insulin glycosylation process of 
in its initial stage occurs  in quasi-equilibrium regime not only at the first stage but also 
according to path reaction 3, therefore its course in time t still obeys integral kinetic equation of 
step 2, expressed in logarithmic form: ( )( ) atссс eqeq =− IF,IF,IFln , wherein parameters eqс ,IF  and 
а  depend on the initial concentration of glutathione 0,Yс . This means that G-SH is able to 
decrease accumulation of FA in the model system in a dose-dependent way. 
On the basis of calculations of the equilibrium constant of step 3 ])[,(3 k
c cTК , it was 
found that the absolute value of the stoichiometric coefficient of insulin α = 4. In practice this 
means that in the model system, one molecule of glutathione reacts with four molecules of 
insulin. This result is quite unexpected because of the large values of α = 4, so it requires to be 
further discussed in terms of the mechanism of interaction of insulin with G-SH. Probably, G-SH 
is able to non-covalently interact with polar functional groups in insulin molecule, thereby 
changing the conformation of the protein. It is also known that insulin in solution forms 
aggregates – tetra- and hexamers. Dissociation of these complexes into monomers can increase 
the availability of amino groups for glycosylation, therefore slowing down of dissociation in the 
presence of glutathione is capable of inhibiting the process. 
Thus, the current study proposed and experimentally confirmed the kinetic model of the 
non-enzymatic glycosylation of genetically engineered human insulin in vitro. It is found that in 
the range of physiological concentrations natural thiol G-SH has a dose-dependent ability to 
inhibit glycosylation of insulin with glucose in vitro, kinetic analysis of the process was 
performed. 
 
  
 
 
 
19 
 
Conclusions: 
 
1. Shown that the 1,3,4-TD and 2,4-substituted thiazole derivatives are able to inhibit the 
accumulation of NGP products while incubating BSA with glucose. The best antiglycosylation 
properties have 5-phenyl-1,3,4-TD derivatives having an oxygen-containing heteryl or 
alkylamino substituent at 2-position. 
2. When evaluating lipophilicity of potential NGP inhibitors – 1,3,4-TD derivatives in 
water/octanol – was established that the partition coefficient lgКow for active NGP inhibitors was 
2.90 - 3.19, while for the less active inhibitors it was 3.14 - 4.02.  
3.  1,3,4-TD derivatives have ability to inhibit the oxidation of ascorbic acid with 
atmospheric oxygen. The most active compounds are N-32, TD-79, L-92, L-17, L-34.  
4. Derivatives of 1,3,4-TD (L-17, L-14, N-32, L-31, L-91) and  2-guanidinethiazole correct 
metabolic disorders in alloxan DM rats. Studied 1,3,4-TD derivatives decrease hyperglycemia, 
accumulation of products of NGP in blood and internal organs, and also possess antioxidant 
activity. 2-G-4-PT exhibits antioxidant and antiglycosylation activity without affecting the 
severity of hyperglycemia. 
5.  Sulfur-containing heterocyclic compounds, such as 1,3,4-TD and 2,4-substituted thiazole 
derivatives are promising for further studies of antidiabetic activity and its biochemical 
mechanisms in experimental animals.  
6. Screening of 1,3,4-TD derivatives for experimental evaluation of antidiabetic action in 
vivo can be performed based on the results of preliminary testing on the antiglycosylation 
activity in vitro (inhibiting of accumulation of fructosamine during incubation of BSA with 
glucose) antioxidant properties (inhibition of the AA oxidation with atmospheric oxygen) and 
ratio of the hydrophilic and lipophilic properties (in "octanol/water"). 
7. Proposed and experimentally confirmed the kinetic model of the non-enzymatic 
glycosylation of genetically engineered human insulin in vitro and its inhibition with G-SH, 
calculated a number of constants of this reaction. 
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1,3,4-ТD – 1,3,4-thiadiazine 
2-G-4-PТ – 2-guanidine-4-pyridinethiazole  
АA – ascorbic acid 
AGE – advanced glycosylation end products 
BSA – bovine serum albumin 
DM – diabetes mellitus  
FA – fructosamine 
FRO – free radical oxidation 
G-SH – glutathione reduced 
G-SS-G – glutathione oxidized 
GEHI – genetically engineered human insulin 
HbAlc – glycosylated hemoglobin 
LA – lipoic acid 
MDA – malonic dialdehyde 
NGP – nonenzymatic glycosylation of proteins 
RAGE – receptor for advanced glycosylation end products 
 
 
 
 
23 
 
